Role of Interleukin 23 in Gastrointestinal GVHD
Role of Interleukin 23 in Gastrointestinal GVHD
批准号:
8961634
负责人:
William R. Drobyski
金额:
$38.29万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-08-01 至 2019-04-30
关键词:
AcuteAddressAffectAllogenicBiologyBone Marrow TransplantationCD4 Positive T LymphocytesCellsClinicalColonComplexComplicationDevelopmentDiseaseEquilibriumEventFosteringFunctional disorderGastrointestinal tract structureGoalsHematopoieticHematopoietic Stem Cell TransplantationHematopoietic stem cellsHomingITGAX geneInflammationInflammatoryIntegrinsInterleukin-10InterleukinsIntestinal Graft Versus Host DiseaseLeadLightMediatingMorbidity - disease rateOrganPathogenicityPathway interactionsPhasePlayPopulationPositioning AttributeProcessProductionReagentReceptor SignalingRegulationRegulatory PathwayRegulatory T-LymphocyteRoleStem cell transplantT-Cell ReceptorT-LymphocyteT-Lymphocyte SubsetsTestingTherapeuticTissuesToxic effectTransgenic MiceTransplant Recipientsbaseclinically relevantclinically significantcytokinedesigngastrointestinalgraft vs host diseaseinsightinterleukin-23mortalitymouse modelneovascularizationnovelpreclinical studypublic health relevancereceptorresearch studystem
中文摘要
英文摘要
DESCRIPTION (provided by applicant): Graft versus host disease (GVHD) is the major complication associated with allogeneic hematopoietic stem cell transplantation. Damage to the gastrointestinal (GI) tract from GVHD is a particularly serious event leading to significant morbidity and mortality. Proinflammatory cytokines play a critical role in the pathophysiology of intestinal GVHD, in part, by activating donor T cell populations which subsequently induce direct tissue damage. In preliminary studies, we have identified interleukin 23 (IL-23) as a pivotal cytokine positioned at the apex of this cytokine cascade that secondarily activates a unique CD4+ IL-23 receptor (IL-23R)-positive T cell population that expresses the β2 integrin, CD11c. The overall goal of this proposal is to define the mechanistic pathways by which this CD4+ T cell subset induces pathological damage and determine the regulatory pathways that counter balance IL-23R-mediated inflammation within the GI tract. Our overall hypothesis is that the β2 integrin, CD11c, defines a novel, pathogenic CD4+ IL-23R+ T cell population that induces colonic inflammation during GVHD, and that is regulated by the Stat3-dependent cytokines, interleukin-10 and interleukin-27. Studies in Specific Aim 1 will be conducted to confirm that CD11c co-expression defines a colitogenic CD4+ IL-23R+ T cell population, determine whether Stat3 dependent cytokines produced during GVHD augment coordinate expression of the IL-23R and CD11c, and examine whether the pathogenicity of β2 integrin-expressing CD4+ T cells is attributable to augmented gut-homing molecule expression on this T cell subset. We will also determine whether this β2 integrin-expressing CD4+ T cell population is able to induce endothelial damage and neovascularization in the colon microenvironment. Studies in Specific Aim 2 will define mechanisms by which CD4+ IL-23R+ T cells are regulated during GVHD. We will test the hypotheses that IL-10 and IL- 27, which are also Stat3 dependent cytokines, play critical roles in the regulation of IL-23R-mediated inflammation in the colon. Proposed experiments will identify and characterize the specific IL-10- producing donor T cell populations most critical for regulating CD4+ IL-23R+ T cells. We will also determine how IL-27 modulates IL-23R-mediated inflammation in the GI tract through effects on both conventional and regulatory T cell populations. These studies will take advantage of unique reagents and transgenic mouse models which will allow us to characterize and define the effects of each of these cytokines in the pathophysiology of gastrointestinal GVHD. The overall objective of this proposal is to develop new insights into the pathophysiology and regulation of GVHD within the GI tract that will foster the development of clinically relevant strategies to mitigate this complication in allogeneic hematopoietic stem cell transplant recipients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Blockade of IL-23 for the Prevention of Graft Versus Host Disease
-
批准号:10391538
-
项目类别:
-
资助金额:$55.82万
-
财政年份:2021
-
负责人:William R. Drobyski
-
依托单位:
Blockade of IL-23 for the Prevention of Graft Versus Host Disease
-
批准号:10612787
-
项目类别:
-
资助金额:$56.64万
-
财政年份:2021
-
负责人:William R. Drobyski
-
依托单位:
Blockade of IL-23 for the Prevention of Graft Versus Host Disease
-
批准号:10209084
-
项目类别:
-
资助金额:$55.82万
-
财政年份:2021
-
负责人:William R. Drobyski
-
依托单位:
Mechanistic Inflammatory Pathways in Graft Versus Host Disease
-
批准号:10410432
-
项目类别:
-
资助金额:$70.02万
-
财政年份:2020
-
负责人:William R. Drobyski
-
依托单位:
Mechanistic Inflammatory Pathways in Graft Versus Host Disease
-
批准号:10214695
-
项目类别:
-
资助金额:$70.02万
-
财政年份:2020
-
负责人:William R. Drobyski
-
依托单位:
Mechanistic Inflammatory Pathways in Graft Versus Host Disease
-
批准号:10627875
-
项目类别:
-
资助金额:$70.02万
-
财政年份:2020
-
负责人:William R. Drobyski
-
依托单位:
Cannabinoid-mediated mitigation of graft versus host disease: Roles of CB2 receptors and adenosine signaling
-
批准号:9402352
-
项目类别:
-
资助金额:$53.87万
-
财政年份:2017
-
负责人:William R. Drobyski
-
依托单位:
Inflammatory Cytokine Networks in Gastrointestinal Tract Graft Versus Host Disease
-
批准号:10159292
-
项目类别:
-
资助金额:$50.42万
-
财政年份:2015
-
负责人:William R. Drobyski
-
依托单位:
Inflammatory Cytokine Networks in Gastrointestinal Tract Graft Versus Host Disease
-
批准号:9903428
-
项目类别:
-
资助金额:$50.42万
-
财政年份:2015
-
负责人:William R. Drobyski
-
依托单位:
Inflammatory Cytokine Networks in Gastrointestinal Tract Graft Versus Host Disease
-
批准号:10374903
-
项目类别:
-
资助金额:$50.42万
-
财政年份:2015
-
负责人:William R. Drobyski
-
依托单位:
Role of Interleukin 23 in the Pathophysiology of GVH and GVL Reactivity
-
批准号:8053836
-
项目类别:
-
资助金额:$31.22万
-
财政年份:2010
-
负责人:William R. Drobyski
-
依托单位:
Role of Interleukin 23 in the Pathophysiology of GVH and GVL Reactivity
-
批准号:7780651
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2010
-
负责人:William R. Drobyski
-
依托单位:
Role of Interleukin 23 in the Pathophysiology of GVH and GVL Reactivity
-
批准号:8206810
-
项目类别:
-
资助金额:$31.22万
-
财政年份:2010
-
负责人:William R. Drobyski
-
依托单位:
Role of Interleukin 23 in the Pathophysiology of GVH and GVL Reactivity
-
批准号:8386898
-
项目类别:
-
资助金额:$30.13万
-
财政年份:2010
-
负责人:William R. Drobyski
-
依托单位:
Graft Versus Host Disease and Autoimmunity
-
批准号:7390654
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2007
-
负责人:William R. Drobyski
-
依托单位:
Graft Versus Host Disease and Autoimmunity
-
批准号:7586674
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2007
-
负责人:William R. Drobyski
-
依托单位:
Graft Versus Host Disease and Autoimmunity
-
批准号:7786243
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2007
-
负责人:William R. Drobyski
-
依托单位:
Graft Versus Host Disease and Autoimmunity
-
批准号:7196195
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2007
-
负责人:William R. Drobyski
-
依托单位:
Augmentation of GVL Reactivity Without GVHD
-
批准号:7881673
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2000
-
负责人:William R. Drobyski
-
依托单位:
MODULATING GVH/GVL POST-BMT USING TK EXPRESSING T CELLS
-
批准号:6084051
-
项目类别:
-
资助金额:$32.5万
-
财政年份:2000
-
负责人:William R. Drobyski
-
依托单位:
海外基金